Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Following the exercise of stock options, 136,700 new common shares will be issued and additionally listed on May 22, 2024.
📊 [Key Disclosure Details & Financial Highlights]
- Company Name & Ticker: ALTEOGEN Inc. (A196170)
- Type and Number of Additional Shares: 136,700 Common Shares
- Par Value Per Share: KRW 500
- Total Listed Shares After Additional Listing: 53,148,528 Common Shares
- Listing Date: 2024-05-22
- Dividend Accrual Date: 2024-01-01
- Detailed Issuance Breakdown (Total 136,700 shares / Issuance Date: 2024-05-03):
- 95th Tranche: 16,000 shares (Exercise Price: KRW 8,889)
- 96th Tranche: 20,100 shares (Exercise Price: KRW 10,000)
- 97th Tranche: 60,000 shares (Exercise Price: KRW 8,917)
- 98th Tranche: 22,400 shares (Exercise Price: KRW 21,111)
- 99th Tranche: 8,600 shares (Exercise Price: KRW 23,833)
- 100th Tranche: 9,600 shares (Exercise Price: KRW 72,875)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Why Verifying Additional Listing and Changes in Total Shares Outstanding Is Necessary
This filing is an informational disclosure notifying the listing schedule and exercise prices across tranches for 136,700 new common shares resulting from stock option exercises.
Checking this follow-up item is necessary because confirming that the total number of listed shares is updated to 53,148,528 according to the scheduled listing date (May 22, 2024) is essential. Verifying that the official share count changes align with the disclosed details in upcoming periodic reports or future filings ensures the final verification of the disclosed facts.
The details can be verified in future disclosures or upcoming periodic reports on DART.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For inquiries regarding regulatory compliance or copyright requests, please contact ksb220805@gmail.com.
